Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 3:47 AM
Ignite Modification Date:
2025-12-26 @ 2:35 AM
NCT ID:
NCT02078102
Group ID:
EG000
Title:
Multiple Myeloma
Description:
This is for the patients with Multiple Myeloma.
Meloxicam and Filgrastim will be administered in fixed doses to each patient enrolled on this study. The treatments will be administered in a staggered dose schedule for a total treatment duration of 7 days prior to apheresis.
15 mg tablets of Meloxicam will be taken orally for 5 consecutive days.
10 µg/kg of Filgrastim will be subcutaneously injected for 5 consecutive days. Filgrastim may be subcutaneously injected for an additional 3 days if patients do not meet the primary endpoint for cell collection.
Meloxicam: 15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
Filgrastim: Filgrastim will be subcutaneously injected in one or two sites at home.
Deaths Number Affected:
4
Deaths Number At Risk:
None
Serious Number Affected:
1
Serious Number At Risk:
25
Other Number Affected:
10
Other Number At Risk:
25
Study:
NCT02078102
Results Section:
NCT02078102
Adverse Events Module:
NCT02078102